Your browser is no longer supported. Please, upgrade your browser.
Settings
NVCR [NASD]
NovoCure Limited
Index- P/E2350.71 EPS (ttm)0.07 Insider Own1.60% Shs Outstand101.23M Perf Week-2.22%
Market Cap17.02B Forward P/E384.46 EPS next Y0.43 Insider Trans-26.63% Shs Float86.71M Perf Month-3.61%
Income7.90M PEG- EPS next Q0.10 Inst Own83.80% Short Float6.19% Perf Quarter32.95%
Sales449.60M P/S37.86 EPS this Y89.30% Inst Trans15.41% Short Ratio4.90 Perf Half Y145.56%
Book/sh3.03 P/B54.31 EPS next Y79.83% ROA3.90% Target Price136.00 Perf Year89.14%
Cash/sh2.27 P/C72.59 EPS next 5Y- ROE7.40% 52W Range53.40 - 182.74 Perf YTD-4.91%
Dividend- P/FCF422.40 EPS past 5Y40.20% ROI0.20% 52W High-9.95% Beta1.04
Dividend %- Quick Ratio3.70 Sales past 5Y86.70% Gross Margin77.10% 52W Low208.15% ATR8.08
Employees782 Current Ratio4.00 Sales Q/Q44.10% Oper. Margin4.10% RSI (14)49.22 Volatility4.37% 4.53%
OptionableYes Debt/Eq0.00 EPS Q/Q376.30% Profit Margin4.30% Rel Volume0.38 Prev Close167.19
ShortableYes LT Debt/Eq0.00 EarningsOct 29 BMO Payout0.00% Avg Volume1.10M Price164.55
Recom2.80 SMA20-2.96% SMA507.21% SMA20063.28% Volume416,570 Change-1.58%
Jan-25-21Reiterated Piper Sandler Overweight $140 → $225
Sep-23-20Initiated Northland Capital Outperform $200
Sep-18-20Downgrade Wells Fargo Overweight → Equal Weight $116
Sep-17-20Downgrade Truist Buy → Hold $108
Jun-01-20Resumed Oppenheimer Perform
May-01-20Downgrade Oppenheimer Outperform → Perform
Apr-09-20Downgrade Evercore ISI In-line → Underperform $58
Mar-05-20Upgrade Wells Fargo Equal Weight → Overweight $85 → $90
Jan-02-20Downgrade Evercore ISI Outperform → In-line $84 → $90
Jul-29-19Upgrade SunTrust Hold → Buy
Jul-26-19Downgrade Wedbush Outperform → Neutral $57 → $80
Jul-26-19Downgrade JP Morgan Overweight → Neutral $61 → $79
Mar-20-19Initiated SunTrust Hold
Nov-02-18Downgrade Wells Fargo Outperform → Market Perform
Jul-16-18Initiated Evercore ISI Outperform $46
Apr-18-18Reiterated Mizuho Buy $28 → $32
Feb-23-18Reiterated Mizuho Buy $25 → $28
May-24-17Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16Reiterated Wedbush Outperform $30 → $20
Jan-19-16Initiated Barclays Underweight $16
Jan-24-21 09:45AM  
Jan-15-21 08:34AM  
Jan-11-21 06:00AM  
Jan-04-21 12:43PM  
Dec-23-20 07:30AM  
Dec-19-20 09:32PM  
Dec-14-20 01:00AM  
Dec-10-20 07:30AM  
Dec-07-20 12:15PM  
03:06AM  
Dec-04-20 05:04PM  
04:12PM  
03:04PM  
10:14AM  
Dec-01-20 07:00AM  
Nov-25-20 07:30AM  
Nov-24-20 03:40PM  
11:41AM  
Nov-23-20 04:51PM  
Nov-21-20 08:00AM  
Nov-20-20 11:34AM  
Nov-19-20 05:30PM  
04:51PM  
08:00AM  
Nov-14-20 05:58AM  
Nov-11-20 07:30AM  
Nov-10-20 07:30AM  
Nov-09-20 07:30AM  
Nov-05-20 04:00PM  
03:40PM  
Nov-04-20 03:25PM  
11:26AM  
Nov-02-20 08:52PM  
07:04AM  
Oct-30-20 12:04AM  
Oct-29-20 06:00AM  
06:00AM  
06:00AM  
Oct-28-20 12:26PM  
06:15AM  
Oct-23-20 11:50AM  
Oct-09-20 08:23AM  
Oct-07-20 12:11PM  
Oct-05-20 03:27PM  
Oct-02-20 11:30AM  
08:56AM  
Sep-29-20 07:30AM  
Sep-28-20 08:43PM  
Sep-25-20 04:00PM  
Sep-24-20 12:41PM  
Sep-23-20 11:25AM  
Sep-09-20 03:12PM  
Sep-04-20 07:30AM  
Aug-29-20 08:00AM  
Aug-24-20 03:29PM  
Aug-13-20 11:37AM  
08:30AM  
Jul-30-20 09:01PM  
06:00AM  
Jul-28-20 07:30AM  
Jul-24-20 09:37PM  
Jul-23-20 12:33PM  
12:00PM  
Jul-22-20 07:30AM  
Jul-15-20 04:38PM  
09:10AM  
07:30AM  
Jul-12-20 08:54PM  
Jul-08-20 07:30AM  
06:00AM  
Jul-07-20 07:30AM  
Jul-01-20 07:30AM  
Jun-18-20 12:02PM  
Jun-08-20 01:07AM  
Jun-02-20 07:30AM  
May-13-20 10:10AM  
May-05-20 11:30PM  
May-04-20 10:21AM  
May-02-20 11:30AM  
Apr-30-20 04:05PM  
07:30AM  
06:00AM  
Apr-27-20 07:30AM  
Apr-23-20 12:32PM  
Apr-07-20 03:07PM  
09:00AM  
Apr-03-20 07:30AM  
Mar-23-20 12:24AM  
Mar-20-20 09:16AM  
Mar-19-20 07:30AM  
Mar-12-20 07:30AM  
Mar-10-20 03:18AM  
Feb-27-20 07:30AM  
06:00AM  
Feb-20-20 12:31PM  
Feb-11-20 08:54AM  
Feb-05-20 09:15AM  
Feb-04-20 02:56PM  
Jan-29-20 09:15AM  
Jan-23-20 07:24AM  
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longsworth Todd ChristopherGeneral CounselJan 15Option Exercise14.3736,396523,011123,474Jan 19 05:00 PM
Longsworth Todd ChristopherGeneral CounselJan 15Sale172.4863,81411,006,64759,660Jan 19 05:00 PM
Benaim ElyChief Medical OfficerDec 21Option Exercise56.932,484141,40631,189Dec 22 06:39 PM
Benaim ElyChief Medical OfficerDec 21Sale156.712,484389,26829,356Dec 22 06:39 PM
Danziger AsafChief Executive OfficerDec 18Option Exercise22.00207,9104,574,020301,587Dec 22 06:37 PM
HILLEMAN JERYL LDirectorDec 18Sale166.402,500416,0003,400Dec 22 06:38 PM
Danziger AsafChief Executive OfficerDec 18Sale157.39207,91032,722,764197,632Dec 22 06:37 PM
Cordova AshleyChief Financial OfficerNov 02Sale117.4123027,00526,212Nov 03 04:23 PM
Shah PriteshChief Commercial OfficerOct 29Option Exercise10.1330,468308,58889,758Oct 30 04:08 PM
Weinberg UriChief Science OfficerSep 25Option Exercise9.6215,250146,75036,347Sep 28 06:13 PM
Weinberg UriChief Science OfficerSep 25Sale103.3515,2501,576,08827,597Sep 28 06:13 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 18Option Exercise7.488,26261,800150,869Sep 21 04:16 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 18Sale109.218,262902,294142,607Sep 21 04:16 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 17Option Exercise7.4812,50093,500155,107Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 17Sale108.6012,5001,357,556142,607Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 16Option Exercise7.2922,012160,369155,107Sep 18 04:37 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 16Sale107.3522,0122,363,014142,607Sep 18 04:37 PM
LEUNG GABRIELDirectorSep 15Option Exercise7.489,56571,54679,437Sep 16 05:27 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 15Option Exercise7.3750,868374,868155,975Sep 16 05:24 PM
Danziger AsafChief Executive OfficerSep 15Option Exercise22.00103,0002,266,000300,632Sep 17 04:32 PM
Danziger AsafChief Executive OfficerSep 15Sale99.00103,00010,197,000197,632Sep 17 04:32 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 15Sale103.2750,8685,253,018142,607Sep 16 05:24 PM
LEUNG GABRIELDirectorSep 15Sale100.009,565956,50072,045Sep 16 05:27 PM
LEUNG GABRIELDirectorSep 14Option Exercise7.4810,00074,80082,045Sep 16 05:27 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 14Option Exercise7.0325,000175,750155,107Sep 16 05:24 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 14Sale98.0125,0002,450,213142,607Sep 16 05:24 PM
LEUNG GABRIELDirectorSep 14Sale95.0010,000950,00072,045Sep 16 05:27 PM
LEUNG GABRIELDirectorSep 10Option Exercise7.4810,00074,80082,045Sep 11 04:15 PM
LEUNG GABRIELDirectorSep 10Sale90.0010,000900,00072,045Sep 11 04:15 PM
LEUNG GABRIELDirectorSep 09Option Exercise7.039,11464,07181,159Sep 11 04:15 PM
LEUNG GABRIELDirectorSep 09Sale85.409,114778,29372,045Sep 11 04:15 PM
Shah PriteshChief Commercial OfficerSep 09Sale85.4128,3212,418,88170,465Sep 11 04:19 PM
LEUNG GABRIELDirectorSep 02Option Exercise7.0310070372,145Sep 04 04:17 PM
LEUNG GABRIELDirectorSep 02Sale85.001008,50072,045Sep 04 04:17 PM
LEUNG GABRIELDirectorAug 25Option Exercise7.037,11249,99779,157Aug 27 04:13 PM
LEUNG GABRIELDirectorAug 25Sale80.137,112569,89272,045Aug 27 04:13 PM
Shah PriteshChief Commercial OfficerAug 04Sale76.812,048157,307101,018Aug 05 04:13 PM
Shah PriteshChief Commercial OfficerAug 03Sale76.411,669127,522103,066Aug 05 04:13 PM
Benaim ElyChief Medical OfficerAug 03Sale76.0666050,20029,356Aug 05 04:11 PM
Shah PriteshChief Commercial OfficerJul 31Option Exercise76.173,717283,124104,735Aug 03 05:39 PM
Benaim ElyChief Medical OfficerJul 31Sale76.3934126,04830,016Aug 03 05:53 PM
DOYLE WILLIAM FExecutive ChairmanJul 31Sale76.3989668,444649,062Aug 03 05:51 PM
LEUNG GABRIELDirectorJul 30Option Exercise7.037,11249,99779,157Aug 03 05:45 PM
LEUNG GABRIELDirectorJul 30Sale75.007,112533,40072,045Aug 03 05:45 PM
LEUNG GABRIELDirectorJul 22Option Exercise7.039,50066,78581,545Jul 23 07:32 PM
Ambrogi Michael J.Chief Operating OfficerJul 22Option Exercise18.4042,972790,640251,639Jul 23 07:43 PM
Ambrogi Michael J.Chief Operating OfficerJul 22Sale67.0242,9722,879,966220,867Jul 23 07:43 PM
LEUNG GABRIELDirectorJul 22Sale67.039,500636,79772,045Jul 23 07:32 PM
LEUNG GABRIELDirectorJul 21Option Exercise7.035003,51572,545Jul 23 07:32 PM
Ambrogi Michael J.Chief Operating OfficerJul 21Option Exercise20.273,32167,332223,888Jul 23 07:43 PM
Ambrogi Michael J.Chief Operating OfficerJul 21Sale65.063,321216,072220,867Jul 23 07:43 PM
LEUNG GABRIELDirectorJul 21Sale65.0750032,53772,045Jul 23 07:32 PM
Benaim ElyChief Medical OfficerMay 12Sale64.782,595168,10412,616May 14 04:14 PM
DOYLE WILLIAM FExecutive ChairmanMay 11Sale63.7331,3321,996,726649,958May 12 04:13 PM
Benaim ElyChief Medical OfficerMay 11Sale63.731,611102,66615,211May 12 04:22 PM
DOYLE WILLIAM FExecutive ChairmanMay 08Option Exercise63.8458,7673,751,685713,193May 11 04:17 PM
Benaim ElyChief Medical OfficerMay 08Option Exercise63.844,206268,51116,822May 12 04:22 PM
Weinberg UriChief Science OfficerMay 08Option Exercise63.841,40289,50425,629May 11 04:22 PM
DOYLE WILLIAM FExecutive ChairmanMay 08Sale63.5031,9032,025,872681,290May 11 04:17 PM
DOYLE WILLIAM FExecutive ChairmanMay 07Option Exercise64.7758,7683,806,403685,419May 11 04:17 PM
DOYLE WILLIAM FExecutive ChairmanMay 07Sale64.7430,9932,006,518654,426May 11 04:17 PM
DOYLE WILLIAM FExecutive ChairmanMay 06Option Exercise64.1558,7683,769,967626,651May 07 04:41 PM
DOYLE WILLIAM FExecutive ChairmanMay 06Sale64.2729,8811,920,452567,883May 07 04:41 PM
DOYLE WILLIAM FExecutive ChairmanMay 05Option Exercise61.4058,7683,608,355628,047May 07 04:41 PM
Shah PriteshChief Commercial OfficerMay 05Sale62.201,14971,468100,693May 07 04:48 PM
DOYLE WILLIAM FExecutive ChairmanMay 05Sale62.4730,2831,891,718597,764May 07 04:41 PM
DOYLE WILLIAM FExecutive ChairmanMay 04Option Exercise60.4858,7683,554,289569,279May 06 05:52 PM
Shah PriteshChief Commercial OfficerMay 04Sale60.081,18471,134101,842May 05 04:32 PM
Shah PriteshChief Commercial OfficerMay 01Option Exercise65.802,333153,511103,026May 05 04:32 PM
Ambrogi Michael J.Chief Operating OfficerApr 14Option Exercise7.1535,745255,577256,612Apr 15 05:03 PM
Ambrogi Michael J.Chief Operating OfficerApr 14Sale71.0027,5191,953,970220,867Apr 15 05:03 PM
Ambrogi Michael J.Chief Operating OfficerApr 13Option Exercise7.1522,755162,698243,622Apr 15 05:03 PM
Ambrogi Michael J.Chief Operating OfficerApr 13Sale69.3230,9812,147,594220,867Apr 15 05:03 PM
Shah PriteshChief Commercial OfficerMar 06Option Exercise7.4817,500130,900103,938Mar 10 04:20 PM
DOYLE WILLIAM FExecutive ChairmanMar 06Sale69.534,320300,387510,511Mar 10 04:18 PM
Longsworth Todd ChristopherGeneral CounselMar 06Sale69.532,499173,76586,753Mar 10 04:15 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerMar 06Sale69.533,123217,155140,386Mar 10 04:13 PM
Ambrogi Michael J.Chief Operating OfficerMar 06Sale69.532,274158,120220,867Mar 10 04:22 PM
Shah PriteshChief Commercial OfficerMar 06Sale66.766,151410,62286,438Mar 10 04:20 PM
Shah PriteshChief Commercial OfficerMar 02Sale72.971,485108,36067,721Mar 05 04:47 PM
Shah PriteshChief Commercial OfficerFeb 28Sale72.221,601115,61669,206Mar 02 05:22 PM
Longsworth Todd ChristopherGeneral CounselFeb 28Sale72.222,643190,86470,032Mar 02 05:11 PM
DOYLE WILLIAM FExecutive ChairmanFeb 28Sale72.223,893281,133514,831Mar 02 05:13 PM
Ambrogi Michael J.Chief Operating OfficerFeb 28Sale72.222,673193,031208,726Mar 02 05:17 PM
Ambrogi Michael J.Chief Operating OfficerFeb 27Option Exercise79.456,173490,445211,399Mar 02 05:17 PM
Danziger AsafChief Executive OfficerFeb 27Option Exercise79.459,259735,628197,348Mar 02 05:15 PM
DOYLE WILLIAM FExecutive ChairmanFeb 27Option Exercise79.459,259735,628518,724Mar 02 05:13 PM
Longsworth Todd ChristopherGeneral CounselFeb 27Option Exercise79.455,556441,42472,675Mar 02 05:11 PM
Shah PriteshChief Commercial OfficerFeb 27Option Exercise79.453,086245,18370,807Mar 02 05:22 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 27Option Exercise0.007,7160119,484Mar 02 05:18 PM
Shah PriteshChief Commercial OfficerFeb 26Sale79.397,932629,72567,721Feb 28 04:41 PM
Shah PriteshChief Commercial OfficerFeb 25Sale81.165,067411,21775,653Feb 28 04:41 PM
Ambrogi Michael J.Chief Operating OfficerFeb 25Sale81.1611,647945,224205,226Feb 26 05:10 PM
Longsworth Todd ChristopherGeneral CounselFeb 25Sale81.168,482688,36567,119Feb 26 05:14 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 25Sale81.1618,9081,534,498111,768Feb 26 05:17 PM
Danziger AsafChief Executive OfficerFeb 24Option Exercise88.2653,3334,707,171188,089Feb 26 05:19 PM
Shah PriteshChief Commercial OfficerFeb 24Option Exercise88.2612,9991,147,29280,720Feb 26 05:18 PM
GROENHUYSEN WILHELMUS CMChief Financial OfficerFeb 24Option Exercise88.2643,3333,824,571130,676Feb 26 05:17 PM
Longsworth Todd ChristopherGeneral CounselFeb 24Option Exercise88.2621,6661,912,24175,601Feb 26 05:14 PM
Ambrogi Michael J.Chief Operating OfficerFeb 24Option Exercise88.2631,1992,753,624216,873Feb 26 05:10 PM